Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $375.26M
• Dividend Yield: N/A
• Average Volume (3M): 3.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: 187.52%
• EPS Growth: 26.32%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 266,141,420
• 10 Day Avg. Volume: 2,089,246
• 30 Day Avg. Volume: 3,257,019
• PEG Ratio: 0.10
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 59.25
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 15.57
• Enterprise Value/Gross Profit: -23.14
• Enterprise Value/Ebitda: -1.97
• 1Y Price Target: $8.52
• Price Target Upside: 504.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.50 ▲(6.38% Upside)

Autolus Therapeutics' overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. The earnings call provided positive insights into product sales and regulatory progress, but high costs and market access issues remain concerns. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable due to the company's unprofitability.

Positive Factors

Revenue Growth

Strong revenue growth from product sales indicates successful market penetration and acceptance, which is crucial for long-term business sustainability.

Regulatory Approvals

Regulatory approvals in key markets enhance market access and potential revenue streams, strengthening the company's competitive position.

Cash Reserves

Strong cash reserves provide financial stability and flexibility to invest in R&D and strategic initiatives, supporting long-term growth.

Negative Factors

High Operational Losses

Continued operational losses highlight challenges in achieving profitability, which can strain resources and impact long-term viability.

Cash Flow Challenges

Delayed cash receipts can hinder operational liquidity, affecting the company's ability to fund ongoing projects and strategic initiatives.

European Market Challenges

Difficulties in European market access limit revenue potential and require strategic adjustments, impacting growth in a key region.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Autolus Therapeutics generates revenue through a combination of product development partnerships, licensing agreements, and potential future product sales. The company collaborates with larger pharmaceutical and biotechnology companies, leveraging their resources and expertise to advance its clinical programs. Key revenue streams include milestone payments from these partnerships upon achieving certain development stages, research funding, and potential royalties from product sales once therapies receive regulatory approval. Additionally, Autolus may benefit from government grants and collaborations aimed at accelerating the development of its innovative therapies.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics shows strong revenue growth but struggles with profitability and cash flow management. Despite a solid balance sheet with substantial cash reserves, ongoing operational losses and negative cash flows present significant challenges.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.93M	10.12M	1.70M	6.19M	2.33M	242.00K
Gross Profit	-20.15M	-1.27M	-4.87M	-131.03M	-126.32M	-134.65M
EBITDA	-236.77M	-233.07M	-156.77M	-135.54M	-132.01M	-160.51M
Net Income	-227.78M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	720.98M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	454.28M	588.02M	239.57M	382.44M	310.34M	153.30M
Total Debt	64.53M	297.23M	52.97M	24.26M	21.00M	54.16M
Total Liabilities	374.52M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	346.46M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-311.99M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-263.02M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-356.81M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	29.42M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.52, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.04 is Neutral, neither overbought nor oversold. The STOCH value of 29.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LRMR	49 Neutral	$325.24M	―	-60.25%	―	―	-40.03%
AUTL	48 Neutral	$375.26M	―	-52.18%	―	187.52%	26.32%
BNTC	47 Neutral	$412.39M	―	-42.31%	―	―	83.28%
DMAC	42 Neutral	$346.83M	―	-73.41%	―	―	-31.78%
CTNM	39 Underperform	$306.67M	-4.61	-30.40%	―	―	-100.71%
TVRD	37 Underperform	$41.17M	-0.25	-93.85%	―	-40.16%	78.28%

Autolus Therapeutics Corporate Events

Autolus Therapeutics’ Earnings Call Highlights Growth and Challenges

The recent earnings call for Autolus Therapeutics highlighted a strong launch and positive reception of their product Obe-cel in the US, alongside significant progress in regulatory approvals and treatment center expansion. However, the company faces challenges with high costs, operational losses, delayed cash receipts, and market access difficulties in Europe.

Autolus Therapeutics Reports Q2 2025 Financial Results

Autolus Therapeutics plc, a biopharmaceutical company, focuses on developing next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.

Autolus Reports Q2 2025 Financial Results

Autolus Therapeutics reported its financial results for Q2 2025, highlighting a net product revenue of $20.9 million from AUCATZYL®, which recently received conditional marketing authorization in the UK and EU. The company is advancing its clinical trials, with plans to initiate a Phase 2 trial in lupus nephritis and a Phase 1 trial in multiple sclerosis by the end of 2025. Despite a net loss of $47.9 million for the quarter, Autolus remains optimistic about its cash position and future growth opportunities, particularly with the promising data from the FELIX trial and the potential of obe-cel in treating autoimmune diseases.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.